Ovarian Cancer Clinical Trials in Cleveland

Showing 41-60 of 213 trials

A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

NCT05360680

This is a Phase 1, open-label, 2-part, multi-center study evaluating the safety, tolerability, PK, pharmacodynamics (PD), immunogenicity, and antitumor activity of CUE-102 intravenous (IV) monotherapy in HLA-A\*0201 positive patients with WT1 positive recurrent/metastatic solid tumors who have failed conventional therapies.

Colorectal CancerGastric CancerPancreatic Cancer+1 more

Cue Biopharma42 participantsStarted Jun 2022

Phoenix, Arizona, United States • Los Angeles, California, United States • Palo Alto, California, United States +12 more locations

Active Not RecruitingPhase 3< 1 mile

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

NCT01844986

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy.

Newly DiagnosedAdvanced Ovarian CancerFIGO Stage III-IV+4 more

AstraZeneca450 participantsStarted Aug 2013

Huntsville, Alabama, United States • Anchorage, Alaska, United States • Phoenix, Arizona, United States +174 more locations

A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

Ovarian Cancer Trials in Other Cities

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Study of AVZO-021 in Patients With Advanced Solid Tumors

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

Nirogacestat in Ovarian Granulosa Cell Tumors

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

A Study of MGC026 in Participants With Advanced Solid Tumors

EXoPERT EMERALD Clinical Study

A Study of PHN-010 in Patients With Advanced Solid Tumors

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer

A Study of PF-06873600 in People With Cancer

Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy

Other Conditions in Cleveland